Login to Your Account

in the clinic NEWS
Spectrum Pharmaceuticals Inc. looked toward another win in its late-stage pipeline as Captisol-enabled (propylene glycol-free) melphalan met the primary endpoints in a pivotal phase II safety and efficacy study.

Evoke Pharma Inc. enrolled the first patient in the phase III trial of EVK-001, its intranasal formulation of metoclopramide, to treat symptoms associated with acute and recurrent diabetic gastroparesis in women.

LONDON – A new era in personalized treatment of cancer begins later this year in the UK with the opening of a phase II trial that will test at least 12 drugs in a single study. Patients with advanced lung cancer will be stratified according to the genetics of their tumors to receive one of the 12 drugs targeted to specific mutations.
More in the clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: